Deep Brain Stimulation for Treatment Refractory PTSD
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03416894|
Recruitment Status : Recruiting
First Posted : January 31, 2018
Last Update Posted : July 25, 2019
|Condition or disease||Intervention/treatment||Phase|
|Post-Traumatic Stress Disorder||Device: Deep Brain Stimulation||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||5 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Deep Brain Stimulation (DBS) for the Treatment of Refractory Post-Traumatic Stress Disorder (PTSD): Pilot Trial|
|Actual Study Start Date :||January 19, 2018|
|Estimated Primary Completion Date :||November 10, 2020|
|Estimated Study Completion Date :||November 10, 2021|
|Experimental: Deep Brain Stimulation||
Device: Deep Brain Stimulation
DBS offers the opportunity to insert electrodes into deep brain structures and electrically stimulate them in a titratable and ultimately reversible manner
- Number of participants with treatment-related adverse events using SAFTEE collateral effects scale. [ Time Frame: 1 year ]Adverse events (AE) will be recorded and categorized according to severity and relationship to procedure. All AEs will be assessed for their relationship to the study procedure.
- Hamilton Depression Rating Scale (HAMD) [ Time Frame: 1 year ]
The HAMD is designed to rate the severity of depression in patients. 0-7 = Normal 8-13 = Mild Depression 14-18 = Moderate Depression 19-22 = Severe Depression
≥ 23 = Very Severe Depression
- Beck's Depression Inventory (BDI) [ Time Frame: 1 year ]BDI is a self-rated depression scale. 1-10:These ups and downs are considered normal;11-16: Mild mood disturbance; 17-20: Borderline clinical depression; 21-30: Moderate depression; 31-40: Severe depression; over 40: Extreme depression
- Beck's Anxiety Inventory (BAI) [ Time Frame: 1 year ]BAI is a self-rated anxiety scale. Score of 0 - 21 = low anxiety Score of 22 - 35 = moderate anxiety Score of 36 and above = potentially concerning levels of anxiety
- Clinician-Administered PTSD Scale (CAPS) [ Time Frame: 1 year ]The CAPS is a semi-structured interview that is designed to assess the essential features of Posttraumatic Stress Disorder.
- Davidson Trauma Scale (DTS) [ Time Frame: 1 year ]Self-report measure that assesses PTSD. The DTS yields a frequency score (ranging from 0 to 68), severity score (ranging from 0 to 68), and total score (ranging from 0 to 136). It can be used to make a preliminary determination about whether the symptoms meet DSM criteria for PTSD. Scores can also be calculated for each of the 3 PTSD symptom clusters (i.e., B, C, and D).
- Short PTSD Rating Interview (SPRINT) [ Time Frame: 1 year ]self-report measure that assesses the core symptoms of PTSD (intrusion, avoidance, numbing, arousal), somatic malaise, stress vulnerability, and role and social functional impairment. Symptoms are rates on five point scales from 0 (not at all) to 4 (very much).
- Clinical Global Impression (CGI) [ Time Frame: 1 year ]CGI is a 3-item observer-rated scale that measures illness severity (CGIS), global improvement or change (CGIC) and therapeutic response. The CGI is rated on a 7-point scale, with the severity of illness scale using a range of responses from 1 (normal) through to 7 (amongst the most severely ill patients). CGI-C scores range from 1 (very much improved) through to 7 (very much worse). Treatment response ratings should take account of both therapeutic efficacy and treatment-related adverse events and range from 0 (marked improvement and no side-effects) and 4 (unchanged or worse and side-effects outweigh the therapeutic effects). Each component of the CGI is rated separately; the instrument does not yield a global score.
- Global Functioning Assessment (GFA) [ Time Frame: 1 year ]
GAF assigns a clinical judgment in numerical fashion to the individual's overall functioning level. Impairments in psychological, social and occupational/school functioning are considered, but those related to physical or environmental limitations are not.
The scale ranges from 0 (inadequate information) to 100 (superior functioning).
- 36-Item Short Form Health Survey (SF-36) [ Time Frame: 1 year ]SF-36 is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting.
- The State-Trait Anxiety Inventory (STAI) [ Time Frame: 1 year ]STAI is a commonly used measure of trait and state anxiety. It can be used in clinical settings to diagnose anxiety and to distinguish it from depressive syndrome. All items are rated on a 4-point scale (e.g., from "Almost Never" to "Almost Always"). Higher scores indicate greater anxiety.
- Hamilton Anxiety Rating Scale (HAMA) [ Time Frame: 1 year ]The scale consists of 14 items, each defined by a series of symptoms, and measures both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.
- Sheehan disability scale (SDS) [ Time Frame: 1 year ]The SDS is a brief, 5-item self-report tool that assesses functional impairment in work/school, social life, and family life. Total score 0-30 (0 unimpaired, 30 highly impaired) Work/school (0-10) Social life (0-10) Family life/home responsibilities (0-10 Scores of ≥5 on any of the 3 scales; high scores are associated with significant functional impairment.
- Positive and negative affect (PANAS) [ Time Frame: 1 year ]
PANAS comprises two mood scales, one that measures positive affect and the other which measures negative affect. Used as a psychometric scale, the PANAS can show relations between positive and negative affect with personality stats and traits. Ten descriptors are used for each PA scale and NA to define their meanings.
Participants in the PANAS are required to respond to a 20-item test using 5-point scale that ranges from very slightly or not at all (1) to extremely (5).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03416894
|Contact: Anusha Baskaran, PhD||416-480-6100 ext firstname.lastname@example.org|
|Sunnybrook Health Sciences Centre||Recruiting|
|Toronto, Ontario, Canada, M4N 3M5|
|Contact: Anusha Baskaran, PhD 416-480-6100 ext 1650 email@example.com|
|Principal Investigator: Nir Lipsman, MD, PhD|
|Principal Investigator: Clement Hamani, MD, PhD|
|Principal Investigator: Anthony Levitt, MD, MBBS|